Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 262

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 262
---
181

    74.5
    %

    Selling, general and administrative

    115,450

    75,543

    39,907

    52.8
    %

    Total cost and operating expenses

    348,431

    206,064

    142,367

    69.1
    %

    Loss from operations

    (217,270
    )

    (206,064
    )

    (11,206
    )

    5.4
    %

    Non-operating income (expense):

    Gain from sale of priority review voucher

    108,000

    —

    108,000

    *

    Investment income, net

    19,701

    17,187

    2,514

    14.6
    %

    Other income (expense), net

    1,217

    (40
    )

    1,257

    *

    Total non-operating income, net

    128,918

    17,147

    111,771

    *

    Loss before income taxes

    (88,352
    )

    (188,917
    )

    100,565

    (53.2
    )%

    Income tax expense

    (7,144
    )

    —

    (7,144
    )
     
    *

    Net Loss
     
    $
    (95,496
    )
     
    $
    (188,917
    )
     
    $
    93,421

    (49.5
    )%

* Amount and/or percentage not meaningful

Product revenue, net

For the year ended December 31, 2024, we recorded net product revenue of $57.2 million from sales of OJEMDA in the United States, which included $2.8 million related to our named patient program in territories outside of the United States. Beginning in 2025, Ipsen has assumed primary responsibility for delivering these programs to patients in territories outside of the United States. 

License revenue

For the year ended December 31, 2024, we recorded license revenue of $73.9 million related to the Ipsen License Agreement.

Cost of product revenue

For the year ended December 31, 2024, we recorded cost of product revenue of $5.3 million related to sales of OJEMDA